Select publications

Abushullaih S et al. Incidence and severity of hand-foot syndrome in colorectal cancer patients treated with capecitabine: A single-institution experience. Cancer Invest 2002;20(1):3-10. Abstract

Agafitei RD et al. Effect of celecoxib on neurotoxicity in patients with metastatic colorectal cancer treated with 5-FU/oxaliplatin (CIFOX). Proc ASCO 2004;Abstract 3600.

Andre T et al. Phase II study of an optimized 5FU-oxaliplatin strategy (OPTIMOX2) with celecoxib in metastatic colorectal cancer: A GERCOR study. Proc ASCO 2004;Abstract 3554.

Arkenau HT et al. Phase III trial of infusional 5-fluorouracil/folinic acid plus oxaliplatin (FUFOX) versus capecitabine plus oxaliplatin (CAPOX) as first line treatment in advanced colorectal carcinoma (ACRC): Results of an interim safety analysis. Proc ASCO 2004;Abstract 3546.

Cassidy J et al. Capecitabine (X) vs bolus 5-FU/leucovorin (LV) as adjuvant therapy for colon cancer (the X-ACT study): Efficacy results of a phase III trial. Proc ASCO 2004;Abstract 3509.

Cassidy J et al. XELOX (capecitabine plus oxaliplatin): Active first-line therapy for patients with metastatic colorectal cancer. J Clin Oncol 2004;22(11):2084-91. Abstract

Gamelin L et al. Prevention of oxaliplatin-related neurotoxicity by calcium and magnesium infusions: A retrospective study of 161 patients receiving oxaliplatin combined with 5-fluorouracil and leucovorin for advanced colorectal cancer. Clin Cancer Res 2004;10(12 Pt 1):4055-61. Abstract

Grothey A. Oxaliplatin-safety profile: Neurotoxicity. Semin Oncol 2003;30(4 Suppl 15):5-13. Abstract

Hoff PM et al. Phase II study of capecitabine in patients with fluorouracil-resistant metastatic colorectal carcinoma. J Clin Oncol 2004;22(11):2078-83. Abstract

Lin EH et al. Celecoxib, a selective cyclooxygenase-2 (COX-2) inhibitor, ameliorated capecitabine (X) hand & foot syndrome (HFS) & enhanced survival in metastatic colorectal cancer (MCRC). Proc ASCO 2004;Abstract 3584.

Lin E et al. Effect of celecoxib on capecitabine-induced hand-foot syndrome and antitumor activity. Oncology (Huntingt) 2002;16(12 Suppl 14):31-7. Abstract

O'Connell MJ. Current status of adjuvant therapy for colorectal cancer. Oncology (Huntingt) 2004;18(6):751-5. Abstract

Saltz LB et al. Irinotecan plus fluorouracil/leucovorin (IFL) versus fluorouracil/leucovorin alone (FL) in stage III colon cancer (Intergroup trial CALGB C89803). Proc ASCO 2004;Abstract 3500.

Sargent DJ et al. Disease-free survival (DFS) vs. overall survival (OS) as a primary endpoint for adjuvant colon cancer studies: Individual patient data from 12,915 patients on 15 randomized trials. Proc ASCO 2004;Abstract 3502.

Scheithauer W et al; X-ACT Study Group. Oral capecitabine as an alternative to i.v. 5-fluorouracilbased adjuvant therapy for colon cancer: Safety results of a randomized, phase III trial. Ann Oncol 2003;14(12):1735-43. Abstract

Thun MJ et al. Nonsteroidal anti-inflammatory drugs as anticancer agents: Mechanistic, pharmacologic, and clinical issues. J Natl Cancer Inst 2002;94(4):252-66. Abstract

Van Cutsem E et al. Oral capecitabine vs intravenous 5-fluorouracil and leucovorin: Integrated efficacy data and novel analyses from two large, randomised, phase III trials. Br J Cancer 2004;90(6):1190-7. Abstract